Combination therapies in PsA not so far away: -Case series of 22 patients from large PsA cohort. -Combination therapy in PsA used when difficult to treat skin and msk involvement. -Deucravacitinib was the agent mostly used in combination with bDMARDs. -No major serious adverse https://t.co/YUyvuaJcsE